HLA-B

HLA class I histocompatibility antigen, B alpha chain · P01889 · HLA-B on Sugi Atlas →

0 patent compounds predicted against HLA-B, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to HLA-B by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201) PHASE3COMPLETED
HLA 10/10 Matched Unrelated Donor vs Haploidentical Allogenic Hematopoietic Stem Cell Transplantation PHASE3UNKNOWN
Randomized Study of ATG for Graft Versus Host Disease (GVHD) Prevention in Paediatric Patients Given an Unrelated Donor Stem Cell Transplantation PHASE3UNKNOWN
Evaluation of the Efficacy and Safety of a 4-month Daily Regimen (2HZPM/2HPM) for Treatment of Pulmonary TB PHASE3ACTIVE_NOT_RECRUITING
Intra Bone Marrow Injection Of Unrelated Cord Blood Cells PHASE1/PHASE2UNKNOWN
Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System PHASE1/PHASE2COMPLETED
Post Transplant High-Dose Cy as GvHD Prophylaxis in 1 HLA Mismatched Unrelated HSCT for Myeloid Malignancies PHASE2COMPLETED
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations PHASE2RECRUITING
Mesenchymal Stem Cell Infusion as Prevention for Graft Rejection and Graft-versus-host Disease PHASE2COMPLETED
NK Cell Based Non-Myeloablative Transplantation in Acute Myeloid Diseases PHASE2COMPLETED
Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related Donors PHASE2COMPLETED
Reduced Intensity Conditioning for Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (BMT CTN 1204) PHASE2COMPLETED
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation PHASE1/PHASE2COMPLETED
Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma PHASE2ACTIVE_NOT_RECRUITING
LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma PHASE1COMPLETED
Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies PHASE1WITHDRAWN
Phase I Study of CTL Anti-DP Infusion Post-hematopoietic Stem Cell Transplantation PHASE1RECRUITING
FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Disease Positive Acute Myeloid Leukemia PHASE1NOT_YET_RECRUITING
Clinical Study for the Safety and Therapeutic Efficacy of the AI-QMMM Designed TamavaqTM Personalised Vaccine in Patients With Newly Diagnosed Glioma. EARLY_PHASE1RECRUITING
HLA Matching - Unrelated Umbilical Cord Blood Transplantation nanCOMPLETED
HLA-DQ in Acute Kidney Transplantation Rejection nanCOMPLETED
High Resolution Donor Recipient HLA Matching Level in Unrelated HSCT nanCOMPLETED
Ankylosing Spondylitis nanNOT_YET_RECRUITING
Individualizing Anti-TNF Therapy in Patients With Inflammatory Bowel Disease nanRECRUITING
MRD Testing Before and After Hematopoietic Cell Transplantation for Pediatric Acute Myeloid Leukemia nanCOMPLETED
In Vitro Study of the Biological and Immunological Activity of Imotopes® Candidates on Blood Cells of Patients With Stabilized NMO nanCOMPLETED
The Relationship Between HLA Tissue Compatibility and Biliary Complications in Patients With Liver Transplantation nanCOMPLETED
Role of Human Leukocyte Antigen Matching in Liver Transplantation and Its Relation to Outcomes nanCOMPLETED
HLA-A*02:01 Allele Frequency and the NY-ESO-1 Expression Status in Cancer Patients in Taiwan nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a HLA-B binder may also engage these)

ProteinNameSimilarity
P13749 1.000 P13749 →
P30382 1.000 P30382 →
P30686 1.000 P30686 →
P30379 1.000 P30379 →
P16210 1.000 P16210 →
HLA-A HLA class I histocompatibility antigen, A alpha chain 1.000 landscape →
P18466 1.000 P18466 →
P30383 1.000 P30383 →
P01893 1.000 P01893 →
P13747 1.000 P13747 →
P13751 1.000 P13751 →
P06140 1.000 P06140 →
P30387 1.000 P30387 →
P13748 1.000 P13748 →
P30375 1.000 P30375 →
P30381 1.000 P30381 →
P01897 1.000 P01897 →
P30380 1.000 P30380 →
P13750 0.999 P13750 →
P14426 0.999 P14426 →
P16212 0.999 P16212 →
P01901 0.999 P01901 →
P13752 0.999 P13752 →
P16209 0.999 P16209 →
P01894 0.999 P01894 →
P30516 0.999 P30516 →
P14427 0.998 P14427 →
P30385 0.998 P30385 →
HLA-C HLA class I histocompatibility antigen, C alpha chain 0.998 landscape →
P03991 0.998 P03991 →